IRVINE, Calif.— Presbia PLC, an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens, a proprietary optical lens implant for treating presbyopia, announced the pricing of its initial public offering of 4,166,667 ordinary shares at a public offering price of $10.00 per share, before underwriting discounts. All of the ordinary shares are being offered by Presbia.

In addition, Presbia (NASDAQ:LENS) has granted the underwriter a 30-day option to purchase up to an additional 625,000 ordinary shares at the initial public offering price. The shares were to have begun trading on the NASDAQ Global Market on Jan. 29. The offering is expected to close on Feb. 3, 2015, subject to customary closing conditions.

Jefferies LLC is acting as the sole book-running manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on Jan. 28, 2015. The offering will be made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, email: Prospectus_Department@Jefferies.com.

As reported by VMail earlier this month, Todd Cooper was recently named president and CEO of Presbia. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens began in 2014.